"I said tongue in cheek at some point when we had five patients in our study that we had at least 500 people touch a paper for the five patients we had recruited. And that's the opposite in the UK." "Some of the contracts for the trial we are still negotiating even today," he adds. "You know, the U.K. didn't have any of that." The C3PO study recently stopped recruiting patients. It had enrolled about 500 out of a planned 900, but an independent monitoring board concluded that continuing would have been futile. This further casts doubt on the value of convalescent plasma. "I don't see any point in offering plasma outside a clinical trial," Angus at Pitt says. Several trials are still ongoing. And there's still a chance that some of them could identify a group of patients, treated at a particular time with a particular concentration of plasma, who would benefit. So Bouvier at Moun Sinai hasn't given up on it completely. In retrospect, it's understandable why convalescent plasma doesn't help people hospitalized with significant illness, she says. Serious illness is caused primarily by the body's reaction. Respiratory viruses like these don't persist for long. "They're sort of like, 'wham, bam, thank you, ma'am' And then they're gone," she says. "If a study comes along comes along that identifies a population in whom convalescent plasma is useful, we will use it in that population" she says. And if it does appear to be helpful for people who are early in the course of disease, that raises another question: Would plasma be better than the monoclonal antibody drugs already authorized by the Food and Drug Administration for that purpose and easier to use? FREE ROBUX CODES FREE ROBUX GENERATOR FREE ROBUX ROBLOX FREE ROBUX 2021 FREE ROBUX GENERATOR APP 2021 Casadevall at Hopkins argues plasma might be better, especially if new virus variants can evade the antibody drugs. Antibodies in the plasma of people who have recovered have apparently been successful in controlling whatever virus they encountered, so the treatment actually evolves along with the pandemic. But to figure out whether convalescent plasma is better than monoclonal antibodies could require another large, time-consuming study in a research system not set up to be nimble.